CVN424

ID: cvn424

Aliases: CVN-424

Type: compound

Route/form: oral investigational drug

Status: investigational

Evidence level: human RCT

Best data tier: human controlled/review; exact-use indirect

Support scope: human, non-human/mechanistic

Source types: early_human, human_rct, preclinical

Linked sources: 3

Broad outcomes: Brain / mood / sleep

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• GPR6 inverse agonism
• striatal indirect pathway

Optimization domains

• cognitive support
• parkinsons disease
• motor function
• early clinical

Research basis

• A phase 2 Parkinson's disease study reported acceptable tolerability and a clinically meaningful daily OFF-time signal at the 150 mg dose.
• Adds a modern CNS investigational program with human data to the graph.

Limits, risks, and missing evidence

• The study was short and small, and the endpoint is Parkinson's motor state rather than general cognition.
• Not a general nootropic despite optimization interest in CNS mechanisms.

Risk flags

• investigational
• disease specific
• limited trial duration
• CNS drug

Linked papers, labels, and reviews

1. CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations
   human_rct / pubmed_cvn424_phase2_2024
   Double-blind randomized phase 2 trial in Parkinson's disease OFF-time.
2. A Phase I, First-in-Human, Healthy Volunteer Study of CVN424
   early_human / pubmed_cvn424_phase1_2022
   First-in-human safety, tolerability, and pharmacokinetics source for oral CVN424.
3. Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease
   preclinical / pubmed_cvn424_development_2021
   Preclinical pharmacology and Parkinson disease model source for GPR6 inverse agonism.